These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 24549815

  • 21. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
    Li J, Chen Y, Wan J, Liu X, Yu C, Li W.
    Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
    [Abstract] [Full Text] [Related]

  • 22. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
    Qin J, Yuan J, Li L, Liu H, Qin R, Qin W, Chen B, Wang H, Wu K.
    Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
    [Abstract] [Full Text] [Related]

  • 23. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [Abstract] [Full Text] [Related]

  • 24. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
    Chen L, He Y, Huang H, Liao H, Wei W.
    Med Oncol; 2008 Oct; 25(2):161-71. PubMed ID: 18172786
    [Abstract] [Full Text] [Related]

  • 25. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM.
    Cancer Res; 2005 Feb 15; 65(4):1459-70. PubMed ID: 15735034
    [Abstract] [Full Text] [Related]

  • 26. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C, Ren J, Zhong G, Shi H, Yuan Z, Su X, Zhu W.
    Int J Mol Med; 2013 Jan 15; 31(1):33-42. PubMed ID: 23128378
    [Abstract] [Full Text] [Related]

  • 27. Curcumin induces apoptosis and inhibits growth of orthotopic human non-small cell lung cancer xenografts.
    Lev-Ari S, Starr A, Katzburg S, Berkovich L, Rimmon A, Ben-Yosef R, Vexler A, Ron I, Earon G.
    J Nutr Biochem; 2014 Aug 15; 25(8):843-50. PubMed ID: 24835302
    [Abstract] [Full Text] [Related]

  • 28. AEE788 potentiates celecoxib-induced growth inhibition and apoptosis in human colon cancer cells.
    Venkatesan P, Bhutia SK, Singh AK, Das SK, Dash R, Chaudhury K, Sarkar D, Fisher PB, Mandal M.
    Life Sci; 2012 Oct 22; 91(15-16):789-99. PubMed ID: 22922496
    [Abstract] [Full Text] [Related]

  • 29. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
    Yun SM, Jung KH, Lee H, Son MK, Seo JH, Yan HH, Park BH, Hong S, Hong SS.
    Cancer Lett; 2013 May 01; 331(2):250-61. PubMed ID: 23340175
    [Abstract] [Full Text] [Related]

  • 30. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
    Katiyar SK, Meeran SM, Katiyar N, Akhtar S.
    Mol Carcinog; 2009 Jan 01; 48(1):24-37. PubMed ID: 18459128
    [Abstract] [Full Text] [Related]

  • 31. Antitumor activity of acriflavine in lung adenocarcinoma cell line A549.
    Lee CJ, Yue CH, Lin YJ, Lin YY, Kao SH, Liu JY, Chen YH.
    Anticancer Res; 2014 Nov 01; 34(11):6467-72. PubMed ID: 25368247
    [Abstract] [Full Text] [Related]

  • 32. Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
    He X, Zhang T.
    Cell Biochem Biophys; 2014 Mar 01; 68(2):411-8. PubMed ID: 23990130
    [Abstract] [Full Text] [Related]

  • 33. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies.
    Xue X, Sun DF, Sun CC, Liu HP, Yue B, Zhao CR, Lou HX, Qu XJ.
    Lung Cancer; 2012 Jun 01; 76(3):300-8. PubMed ID: 22261315
    [Abstract] [Full Text] [Related]

  • 34. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X.
    Cancer Chemother Pharmacol; 2007 Feb 01; 59(2):183-95. PubMed ID: 16724239
    [Abstract] [Full Text] [Related]

  • 35. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
    Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM, Peled A, Wald O.
    J Thorac Cardiovasc Surg; 2012 Nov 01; 144(5):1167-1175.e1. PubMed ID: 22925564
    [Abstract] [Full Text] [Related]

  • 36. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
    Zhang XH, Shin JY, Kim JO, Oh JE, Yoon SA, Jung CK, Kang JH.
    Cancer Lett; 2012 Sep 28; 322(2):213-22. PubMed ID: 22433711
    [Abstract] [Full Text] [Related]

  • 37. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 28; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 38. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY, Xu YP, Jin W, Lou LG.
    Anticancer Drugs; 2012 Aug 28; 23(7):698-705. PubMed ID: 22441567
    [Abstract] [Full Text] [Related]

  • 39. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin.
    Zhao S, Cai J, Bian H, Gui L, Zhao F.
    Cancer Invest; 2009 Jul 28; 27(6):636-40. PubMed ID: 19387877
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M, Tsuji S, Tsujii M, Irie T, Komori M, Kimura A, Nishida T, Kakiuchi Y, Kawai N, Murata H, Horimoto M, Sasaki Y, Hayashi N, Kawano S, Hori M.
    Cancer Res; 2003 Oct 15; 63(20):6726-34. PubMed ID: 14583467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.